Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241436 · ClinicalTrials.gov registry record · Phase 2
Open Label Arimidex in Gynecomastia
A Phase 2 study of Gynecomastia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00241436: Completed Phase 2 study of Gynecomastia, sponsored by AstraZeneca.
NCT00241436 is a Phase 2 study of Gynecomastia that has completed, run by AstraZeneca. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00241436, a Phase 2 study of Gynecomastia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, effectiveness, pharmacokinetics and pharmacodynamics of anastrozole (ARIMIDEX™) in the treatment of boys with gynecomastia.
Conditions Studied
Interventions
- DRUG Anastrozole (ARIMIDEX™)
Study Locations (1)
Florida
- Research Site - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00241436 record still lists
NCT00241436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Gynecomastia appearing as the primary indexed condition, and to 1 intervention - of which Anastrozole (ARIMIDEX™) is the first listed.
NCT00241436 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00241436 about?
NCT00241436 is a clinical study titled "Open Label Arimidex in Gynecomastia". The purpose of this study is to evaluate the safety, effectiveness, pharmacokinetics and pharmacodynamics of anastrozole (ARIMIDEX™) in the treatment of boys with gynecomastia.
What is the current status of trial NCT00241436?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-06. Estimated completion is 2006-11.
What conditions does trial NCT00241436 study?
This clinical trial studies the following conditions: Gynecomastia.
What interventions are being tested in trial NCT00241436?
The interventions under investigation include: Anastrozole (ARIMIDEX™) (DRUG).
Who is sponsoring clinical trial NCT00241436?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00241436 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00241436's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia